ProbeChem®
Expedite Your Scientific Research

WWW.PROBECHEM.COM

Data Sheet

Global Supplier of Chemical Probes, Inhibitors & Agonists.

Product Name	:	PF-114
Cat. No.	:	PC-20215
CAS No.	:	1416241-23-0
Molecular Formula	:	$C_{29}H_{27}F_3N_6O$
Molecular Weight	:	532.57
Target	:	Bcr-Abl
Solubility	:	10 mM in DMSO



Biological Activity

Vamotinib (PF-114) is a potent, selective and orally available inhibitor of native (IC50=0.49 nM) and mutated **BCR/ABL** (IC50=0.7-4 nM, ABL (T315I) IC50=0.78 nM).
PF-114 potently inhibits ABL2, DDR1, DDR2, FMS, FRK, LCK, LYN and PDGFR kinases, but did not inhibit c-SRC, CSK, or c-KIT.
PF-114 is a potent TKI with a more restricted selectivity profile as compared to ponatinib or dasatinib.
PF-114 inhibits the autophosphorylation of BCR/ABL and BCR/ABL-T315I and abolishes factor-independent growth of Ba/F3 cells mediated by BCR/ABL and its resistance mutants.
PF-114 potently inhibits Ph+ patient derived cell lines, abolishes tumor growth in a K562 nude-mouse xenograft model.
PF-114 suppresses growth of Ph+ PD-LTC with non mutational resistance as well as T315I mutation.
PF-114 prolongs the survival of mice with both BCR/ABL- and BCR/ABL-T315I-driven CMLlike disease.

References

A A Mian, et al. ***Leukemia.*** 2015 May;29(5):1104-14.

Ivanova ES, et al. ***Int J Oncol.*** 2019 Jul;55(1):289-297.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com